mTOR

mTOR
Name	mTOR
Organism	Homo sapiens
Other names	mechanistic target of rapamycin
Uniprot	P42345

mTOR mTOR is a serine/threonine protein kinase that serves as a central regulator of cell growth, metabolism, and homeostasis by integrating signals from nutrients, growth factors, energy status, and stress. Discovered in studies involving Streptomyces hygroscopicus natural products and characterized through work at institutions including the University of Basel, Harvard Medical School, and the Whitehead Institute, mTOR operates within conserved signaling networks that connect receptors such as Insulin receptor and Epidermal growth factor receptor to downstream effectors that control translation, autophagy, and lipid synthesis.

Function and Biological Role

mTOR controls anabolic and catabolic balance through phosphorylation of substrates that include components of the translational machinery and autophagy regulators, linking inputs from Insulin receptor, Insulin-like growth factor 1 receptor, AMP-activated protein kinase, Ras, and PI3K. By coordinating activities of ribosomal protein synthesis factors such as S6 kinase 1 and 4E-BP1, mTOR influences cell size, proliferation, and survival in contexts studied by laboratories at Massachusetts Institute of Technology, National Institutes of Health, and Max Planck Society. mTOR signaling also interfaces with metabolic hubs regulated by PPARγ, SREBP1, and mitochondrial regulators examined by teams at Stanford University and the University of Cambridge.

Structure and Complexes (mTORC1 and mTORC2)

mTOR assembles into two distinct multiprotein complexes, each defined by unique scaffolding and regulatory subunits characterized in structural biology work at European Molecular Biology Laboratory and Protein Data Bank deposits. mTOR complex 1 (mTORC1) contains Raptor and PRAS40 and is sensitive to inhibition by the macrolide rapamycin discovered from Eli Lilly and Company-sponsored natural product screens; mTORC1 phosphorylates S6 kinase 1 and 4E-BP1. mTOR complex 2 (mTORC2) includes Rictor, mSin1, and Protor and controls phosphorylation of AGC kinases such as Akt (protein kinase B) and PKCα, with structural insight contributed by cryo-electron microscopy labs at University of Oxford and Harvard University.

Regulation and Signaling Pathways

Upstream regulation of mTOR complexes involves canonical pathways studied in cell biology by groups at Columbia University and Johns Hopkins University. Nutrient sensing uses the Rag GTPase–Ragulator axis and lysosomal recruitment mechanisms linked to v-ATPase and Lysosome (organelle). Growth factor inputs are transduced through PI3K–AKT1 signaling and counterbalanced by tumor suppressors including PTEN and TSC1/TSC2, with TSC complex acting as a GTPase-activating protein for Rheb. Energy and stress signals converge via AMP-activated protein kinase and REDD1 to inhibit mTORC1. Crosstalk with pathways involving MAPK/ERK, Wnt signaling pathway, and Notch signaling pathway has been delineated in models from research centers such as Salk Institute and Dana-Farber Cancer Institute.

Physiological Roles and Tissue-specific Functions

mTOR signaling underpins developmental and adult physiology across tissues studied at institutions like The Rockefeller University and University College London. In the central nervous system, mTOR modulates synaptic plasticity, memory, and neurodevelopmental processes explored in laboratories at Massachusetts Institute of Technology and Cold Spring Harbor Laboratory. In liver and adipose tissue, mTORC1 regulates lipogenesis through SREBP1 and systemic metabolism investigated by teams at Yale School of Medicine and Imperial College London. In skeletal muscle and cardiac tissues, mTOR influences hypertrophy and protein turnover relevant to work at Cleveland Clinic and Mayo Clinic. Immune cell function and differentiation—T cell activation, dendritic cell metabolism—are shaped by mTOR signaling in studies from Mount Sinai Hospital and National Institute of Allergy and Infectious Diseases.

Clinical Significance and Disease Associations

Dysregulation of mTOR is implicated in diverse pathologies including cancers, metabolic disorders, and neurodegeneration; translational oncology efforts at centers like Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center have linked hyperactive mTOR signaling to tumorigenesis in contexts involving PIK3CA, KRAS, and PTEN mutations. Genetic syndromes such as Tuberous sclerosis complex arise from mutations in TSC1 or TSC2 encoding regulators of mTOR and are managed by multidisciplinary teams at institutions like Johns Hopkins Hospital. Aberrant mTOR activity contributes to insulin resistance and type 2 diabetes studied at Joslin Diabetes Center and to neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease via effects on autophagy and proteostasis characterized by groups at University of California, San Francisco and Karolinska Institutet.

Pharmacology and Therapeutic Targeting

Therapeutic modulation of mTOR began with rapamycin and led to development of rapalogs (e.g., everolimus, sirolimus) used in oncology and transplantation by pharmaceutical companies like Novartis and Pfizer. Second-generation ATP-competitive mTOR inhibitors and dual PI3K/mTOR inhibitors have been advanced by collaborations among AstraZeneca, GlaxoSmithKline, and academic drug discovery units at Broad Institute. Clinical trials coordinated by networks including National Cancer Institute and European Organisation for Research and Treatment of Cancer evaluate combination regimens targeting mTOR alongside agents against EGFR, MEK, and PD-1 immune checkpoints. Resistance mechanisms involving feedback activation of PI3K or upregulation of Ras–ERK signaling continue to motivate translational research at Fred Hutchinson Cancer Center and consortia such as Stand Up To Cancer.

Category:Signal transduction proteins